Takeda Pharmaceutical

OverviewSuggest Edit

Takeda Pharmaceutical is a biopharmaceutical company. It develops and markets pharmaceutical products in oncology, rare genetics and hematology, neuroscience, and gastroenterology, as well as plasma-derived therapies and vaccines. Its products in the key business areas include the following brands: ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG.

TypePublic
Founded1781
HQTokyo, JP
Websitetakeda.com
Employee Ratings4
Overall CultureA

Latest Updates

Employees (est.) (Mar 2021)47,099
Job Openings1,769
Revenue (FY, 2021)¥3.2 T(-2%)
Share Price (May 2022)¥3.7 K(+2%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Takeda Pharmaceutical

Andrew S. Plump

Andrew S. Plump

Director, President, Research & Development
Christophe Weber

Christophe Weber

Representative Director, President & CEO
Costa Saroukos

Costa Saroukos

Director, Chief Financial Officer
Masato Iwasaki

Masato Iwasaki

Representative Director Japan General Affairs
Marcello Agosti

Marcello Agosti

Global Business Development Officer
Teresa Bitetti

Teresa Bitetti

President, Global Oncology Business Unit
Show more

Takeda Pharmaceutical Office Locations

Takeda Pharmaceutical has offices in Tokyo, Fujisawa, Fukuchiyama, Hikari and in 55 other locations
Tokyo, JP (HQ)
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku
Fujisawa, JP
26-1, Muraoka-Higashi 2-chome
Fukuchiyama, JP
2-21 Osadano
Hikari, JP
4720, Takeda , Mitsui
Osaka, JP
17-85, Jusohonmachi 2-chome, Yodogawa-ku
Osaka, JP
1 Chome-1 Doshomachi, Chuo Ward
Show all (61)

Takeda Pharmaceutical Financials and Metrics

Takeda Pharmaceutical Revenue

Takeda Pharmaceutical's revenue was reported to be ¥3.2 t in FY, 2021
JPY

Revenue (Q3, 2022)

901.3b

Gross profit (Q3, 2022)

781.9b

Net income (Q3, 2022)

57.8b

EBITDA (Q3, 2022)

380.1b

EBIT (Q3, 2022)

114.8b

Market capitalization (13-May-2022)

5.7t

Closing stock price (13-May-2022)

3.7k

Cash (31-Dec-2021)

724.3b

EV

9.3t
Takeda Pharmaceutical's current market capitalization is ¥5.7 t.
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

1.8t2.1t3.3t3.2t

Cost of goods sold

(313.8b)(387.2b)(506.1b)(434.6b)

Gross profit

1.5t1.8t2.8t2.8t

R&D expense

(325.4b)(368.3b)(492.4b)(455.8b)
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Revenue

449.8b430.8b499.4b849.1b811.0b859.3b801.9b788.9b836.8b949.6b844.8b901.3b

Cost of goods sold

(82.0b)(71.3b)(100.2b)(124.3b)(106.1b)(173.3b)(96.5b)(110.7b)(113.4b)(98.3b)(135.1b)(134.1b)

Gross profit

367.8b359.4b399.2b731.5b709.6b704.5b769.1b684.0b772.4b862.4b718.1b781.9b

R&D expense

(72.0b)(79.5b)(77.5b)(116.9b)(113.5b)(122.7b)(106.8b)(118.2b)(117.6b)(122.5b)(131.6b)(128.4b)
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Cash

294.5b702.1b637.6b966.2b

Accounts Receivable

360.8b657.7b710.0b779.6b

Inventories

212.9b986.7b759.6b753.9b
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Cash

231.5b317.1b297.9b593.7b543.5b568.3b589.8b630.9b617.6b654.9b607.9b724.3b

Accounts Receivable

450.8b461.4b509.5b760.1b779.4b820.7b784.6b754.0b791.5b827.3b843.6b715.5b

Inventories

221.4b233.3b223.4b902.5b840.8b801.3b759.4b743.5b739.4b779.1b783.5b811.3b
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

186.7b109.0b44.3b376.2b

Depreciation and Amortization

182.1b272.4b583.6b559.7b

Inventories

13.7b58.7b137.5b26.0b

Accounts Payable

6.9b(16.4b)(29.9b)36.6b
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Net Income

78.1b126.5b164.4b(20.6b)33.3b42.7b82.5b86.6b179.0b137.7b183.7b241.5b

Depreciation and Amortization

38.6b78.0b116.3b176.3b342.0b437.9b141.6b280.5b420.3b142.9b283.6b430.9b

Inventories

(12.5b)(21.5b)(15.4b)52.6b71.0b92.7b(4.4b)3.0b6.1b(21.0b)(25.0b)(39.3b)

Accounts Payable

(4.7b)(230.0m)24.1b(30.3b)(41.5b)(39.2b)(23.2b)(26.3b)(5.1b)(24.9b)(9.0b)(1.8b)
JPYFY, 2018

EV/EBITDA

1.6 x

EV/EBIT

15.5 x

EV/CFO

1.9 x

Revenue/Employee

65.0m
Show all financial metrics

Takeda Pharmaceutical Operating Metrics

Oct, 2018Feb, 2019May, 2019Jul, 2019Oct, 2019Feb, 2020May, 2020Jul, 2020Oct, 2020

Phase I Trials Products (Oncology)

5311

Phase I/II Trials Products (Oncology)

5443

Phase II Trials Products (Oncology)

79778

Phase III Trials Products (Oncology)

8910777765

Takeda Pharmaceutical Acquisitions / Subsidiaries

Company NameDateDeal Size
PvP BiologicsFebruary 26, 2020$330 m
ShireApril 25, 2018$62 b
TiGenixJanuary 05, 2018€520 m
ARIAD PharmaceuticalsJanuary 09, 2017$5.2 b
InviragenMay 07, 2013
LigoCyte PharmaceuticalsOctober 05, 2012$60 m
IntellikineDecember 21, 2011$310 m
Nycomed PharmaMay 19, 2011€9.6 b
IDM Pharma , Inc.June 24, 2009
Millennium PharmaceuticalsFebruary 01, 2008$8.69 b
Show more

Takeda Pharmaceutical Revenue Breakdown

Embed Graph

Takeda Pharmaceutical revenue breakdown by business segment: 97.1% from ETHICAL DRUG and 2.9% from Other

Takeda Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

D

68/100

SecurityScorecard logo

Takeda Pharmaceutical Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Takeda Pharmaceutical Online and Social Media Presence

Embed Graph

Takeda Pharmaceutical Company Culture

  • Overall Culture

    A

    76/100

  • CEO Rating

    A-

    76/100

  • Compensation

    B+

    75/100

  • Diversity

    A-

    76/100

Learn more on Comparably

Takeda Pharmaceutical News and Updates

Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

Osaka, JAPAN, May 11, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas.

Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in Fiscal Year 2022

Osaka, JAPAN, May 11, 2022 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Company”) announced that the meeting of the Board of Directors held today resolved to continue the stock compensation plan which was introduced as a long-term incentive plan for members of the Board of Director…

Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories

Takeda announced that the ISPE has awarded the company top honors in the Supply Chain and Pharma 4.0 categories

Takeda Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 11

Takeda holds fourth quarter and full-year FY2021 earnings call on May 11

Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

New exploratory analysis showing patients treated with LIVTENCITY™ (Maribavir) had reductions in hospitalization rates and length of hospital stay

Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum

Takeda (TSE:4502/NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topline growth of its 14 global brands. Based on the strong third-quarter results and business momentum, the company upgraded forecasts …
Show more

Takeda Pharmaceutical Frequently Asked Questions

  • When was Takeda Pharmaceutical founded?

    Takeda Pharmaceutical was founded in 1781.

  • Who are Takeda Pharmaceutical key executives?

    Takeda Pharmaceutical's key executives are Andrew S. Plump, Christophe Weber and Costa Saroukos.

  • How many employees does Takeda Pharmaceutical have?

    Takeda Pharmaceutical has 47,099 employees.

  • What is Takeda Pharmaceutical revenue?

    Latest Takeda Pharmaceutical annual revenue is ¥3.2 t.

  • What is Takeda Pharmaceutical revenue per employee?

    Latest Takeda Pharmaceutical revenue per employee is ¥67.9 m.

  • Who are Takeda Pharmaceutical competitors?

    Competitors of Takeda Pharmaceutical include Nipro Corporation, Grifols and Codiak Biosciences.

  • Where is Takeda Pharmaceutical headquarters?

    Takeda Pharmaceutical headquarters is located at 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo.

  • Where are Takeda Pharmaceutical offices?

    Takeda Pharmaceutical has offices in Tokyo, Fujisawa, Fukuchiyama, Hikari and in 55 other locations.

  • How many offices does Takeda Pharmaceutical have?

    Takeda Pharmaceutical has 61 offices.